Treatment of Allergic Rhinitis as a Strategy for Preventing Asthma

  • Jaymin B. Morjaria
  • Massimo Caruso
  • Rosalia Emma
  • Cristina Russo
  • Riccardo Polosa
Rhinitis (JJ Oppenheimer and J Corren, Section Editors)
  • 154 Downloads
Part of the following topical collections:
  1. Topical Collection on Rhinitis

Abstract

Purpose of Review

To evaluate the impact of allergic rhinitis (AR) on the development of asthma and to update readers on recent literature suggesting that early treatment of allergic subjects with immunotherapy may prevent asthma onset.

Recent Findings

AR is frequently associated with asthma, leading to the concept that these two conditions are different aspects of the same disease. There is increasing evidence that AR precedes the onset of asthmatic symptoms and current treatment strategies are beneficial in symptom control with no impact prevention. There is limited knowledge about the risk factors responsible for the progression of AR to asthma, though recent data supports the notion that it is possible to prevent asthma onset by allergen immunotherapy.

Summary

Despite significant advances in specific immunotherapy (SIT) therapy strengthening its efficacy in AR and possible prevention of progression to asthma, the adoption of this therapeutic strategy is still restricted in comparison to therapies directed towards treatment of AR symptoms. Unlike corticosteroids and other symptomatic therapies, the benefit of SIT treatment in allergic individuals has been shown to prevent the development of allergic conditions. Hence, large well-conducted randomized clinical trials with long-term efficacy of SIT are required to confirm or refute the concept that SIT may abrogate the progression of AR to asthma in patients.

Keywords

Allergic rhinitis Asthma Specific immunotherapy SIT Prevention 

Notes

Compliance with Ethical Standards

Conflict of Interest

Dr. Morjaria reports non-financial support from Boehringer Ingelheim, during the conduct of the study; personal fees and other from Boehringer Ingelehim; Chiesi; AstraZeneca; Novartis; Teva UK Ltd; Pfizer; and GlaxoSmithKline, outside the submitted work. The other authors declare no conflicts of interest relevant to this manuscript.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Bro JL, Bousquet J, Agache I, Agarwal A, Bachert C, Bosnic-Anticevich S, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision. 2017.Google Scholar
  2. 2.
    Togias A. Mechanisms of nose-lung interaction. Allergy. 1999;54(s57):94–105.CrossRefPubMedGoogle Scholar
  3. 3.
    Passalacqua G, Ciprandi G, Canonica GW. The nose-lung interaction in allergic rhinitis and asthma: united airways disease. Curr Opin Allergy Clin Immunol. 2001;1(1):7–13.PubMedGoogle Scholar
  4. 4.
    •• Giavina-Bianchi P, Aun MV, Takejima P, Kalil J, Agondi RC. United airway disease: current perspectives. J Asthma Allergy. 2016;9:93–100. This paper gathers epidemiologic, pathophysiologic, and clinical evidence for an integrated view of rhinitis and asthma defining them unitarily as “united airway disease. CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Jeffery CC, Bhutani M, Vliagoftis H, Wright ED, Seikaly H, Côté DWJ. Association between allergic rhinitis and asthma in a Northern Alberta cohort. J Otolaryngol Head Neck Surg. 2013;42(1):58.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Ciprandi G, Cirillo I. The lower airway pathology of rhinitis. J Allergy Clin Immunol. 2006;118(5):1105–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Lin J, Su N, Liu G, Yin K, Zhou X, Shen H, et al. The impact of concomitant allergic rhinitis on asthma control: a cross-sectional nationwide survey in China. J Asthma. 2014;51(1):34–43.CrossRefPubMedGoogle Scholar
  8. 8.
    Bousquet J, Hellings PW, Agache I, Bedbrook A, Bachert C, Bergmann KC, et al. ARIA 2016: care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle. Clin Transl Allergy. 2016;6:47.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Cibella F, Ferrante G, Cuttitta G, Bucchieri S, Melis MR, La Grutta S, et al. The burden of rhinitis and rhinoconjunctivitis in adolescents. Allergy Asthma Immunol Res. 2015;7(1):44–50.CrossRefPubMedGoogle Scholar
  10. 10.
    Navarro AM, Delgado J, Muñoz-Cano RM, Dordal MT, Valero A, Quirce S, et al. Allergic respiratory disease (ARD), setting forth the basics: proposals of an expert consensus report. Clin Transl Allergy. 2017;7:16.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Ciprandi G, Caimmi D, Miraglia Del Giudice M, La Rosa M, Salpietro C, Marseglia GL. Recent developments in United airways disease. Allergy Asthma Immunol Res. 2012;4(4):171–7.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Bonay M, Neukirch C, Grandsaigne M, Leçon-Malas V, Ravaud P, Dehoux M, et al. Changes in airway inflammation following nasal allergic challenge in patients with seasonal rhinitis. Allergy. 2006;61(1):111–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Zhu Z, Xie Y, Guan W, Gao Y, Xia S, Zhong N, et al. FeNO for detecting lower airway involvement in patients with allergic rhinitis. Exp Ther Med. 2016;12(4):2336–40.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Braunstahl G-J, Overbeek SE, Fokkens WJ, Kleinjan A, Mceuen AR, Walls AF, et al. Segmental bronchoprovocation in allergic rhinitis patients affects mast cell and basophil numbers in nasal and bronchial mucosa. Am J Respir Crit Care Med. 2001;164(5):858–65.CrossRefPubMedGoogle Scholar
  15. 15.
    Ciprandi G, Signori A, Tosca MA, Cirillo I. Spirometric abnormalities in patients with allergic rhinitis: Indicator of an “asthma march”? Am J Rhinol Allergy. 2011;25(5):181–5.CrossRefGoogle Scholar
  16. 16.
    Lambrecht BN, Hammad H. Asthma: the importance of dysregulated barrier immunity. Eur J Immunol. 2013;43(12):3125–37.CrossRefPubMedGoogle Scholar
  17. 17.
    Pawankar R, Bunnag C, Khaltaev N, Bousquet J. Allergic rhinitis and its impact on asthma in Asia Pacific and the ARIA update 2008. World Allergy Organ J. 2012;5(Suppl 3):S212–7.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Linneberg A, Henrik Nielsen N, Frølund L, Madsen F, Dirksen A, Jørgensen T, et al. The link between allergic rhinitis and allergic asthma: a prospective population-based study. The Copenhagen Allergy Study. Allergy. 2002;57(11):1048–52.CrossRefPubMedGoogle Scholar
  19. 19.
    • Cirillo I, Ricciardolo FLM, Medusei G, Signori A, Ciprandi G. Exhaled nitric oxide may predict bronchial hyperreactivity in patients with allergic rhinitis. Int Arch Allergy Immunol. 2013;160(3):322–8. This study highlights the relevance of FeNO as a possible predictive marker for BHR in AR patients and underlines the close link between upper and lower airways. CrossRefPubMedGoogle Scholar
  20. 20.
    Lee E, Lee SH, Kwon J-W, Kim Y, Cho H-J, Yang S-I, et al. A rhinitis phenotype associated with increased development of bronchial hyperresponsiveness and asthma in children. Ann Allergy Asthma Immunol. 2016;117(1):21–28.e1.CrossRefPubMedGoogle Scholar
  21. 21.
    Nickel R, Lau S, Niggemann B, Gruber C, von Mutius E, Illi S, et al. Messages from the German multicentre allergy study. Pediatr Allergy Immunol. 2002;13(s15):7–10.CrossRefPubMedGoogle Scholar
  22. 22.
    Spergel J, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112(6):S118–27.CrossRefPubMedGoogle Scholar
  23. 23.
    Asher MI, Montefort S, Björkstén B, Lai CKW, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet (Lond Engl). 2006;368(9537):733–43.CrossRefGoogle Scholar
  24. 24.
    Björkstén B, Clayton T, Ellwood P, Stewart A, Strachan D. Phase III study groupthe I. Worldwide time trends for symptoms of rhinitis and conjunctivitis: phase III of the International Study of Asthma and Allergies in Childhood. Pediatr Allergy Immunol. 2008;19(2):110–24.CrossRefPubMedGoogle Scholar
  25. 25.
    Yoo B, Park Y, Park K, Kim H. A 9-year trend in the prevalence of allergic disease based on national health insurance data. J Prev Med Public Health. 2015;48(6):301–9.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Linneberg A, Dam Petersen K, Hahn-Pedersen J, Hammerby E, Serup-Hansen N, Boxall N. Burden of allergic respiratory disease: a systematic review. Clin Mol Allergy. 2016;14:12.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Sinha B, Vibha, Singla R, Chowdhury R. Allergic rhinitis: a neglected disease—a community based assessment among adults in Delhi. J Postgrad Med. 2015;61(3):169–75.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Bousquet J, Anto JM, Wickman M, Keil T, Valenta R, Haahtela T, et al. Are allergic multimorbidities and IgE polysensitization associated with the persistence or re-occurrence of foetal type 2 signalling? The MeDALL hypothesis. Allergy. 2015;70(9):1062–78.CrossRefPubMedGoogle Scholar
  29. 29.
    Liu AH, Babineau DC, Krouse RZ, Zoratti EM, Pongracic JA, O’Connor GT, et al. Pathways through which asthma risk factors contribute to asthma severity in inner-city children. J Allergy Clin Immunol. 2016;138(4):1042–50.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    • Aguilar D, Pinart M, Koppelman GH, Saeys Y, Nawijn MC, Postma DS, et al. Computational analysis of multimorbidity between asthma, eczema and rhinitis. PLoS One. 2017;12(6):e0179125. This in silico study highlights the molecular mechanisms overlap among AR and asthma. CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    BioCarta_Pathways [Internet]. [cited2017Nov 2]. Available from:https://cgap.nci.nih.gov/Pathways/BioCarta_Pathways.
  32. 32.
    Canonica GW, Compalati E. Minimal persistent inflammation in allergic rhinitis: implications for current treatment strategies. Clin Exp Immunol. 2009;158(3):260–71.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Kurukulaaratchy RJ, Zhang H, Patil V, Raza A, Karmaus W, Ewart S, et al. Identifying the heterogeneity of young adult rhinitis through cluster analysis in the Isle of Wight birth cohort. J Allergy Clin Immunol. 2015;135(1):143–50.CrossRefPubMedGoogle Scholar
  34. 34.
    Braunstahl G-J, Fokkens WJ, Overbeek SE, KleinJan A, Hoogsteden HC, Prins J-B. Mucosal and systemic inflammatory changes in allergic rhinitis and asthma: a comparison between upper and lower airways. Clin Exp Allergy. 2003;33(5):579–87.CrossRefPubMedGoogle Scholar
  35. 35.
    Burgess JA, Walters EH, Byrnes GB, Matheson MC, Jenkins MA, Wharton CL, et al. Childhood allergic rhinitis predicts asthma incidence and persistence to middle age: a longitudinal study. J Allergy Clin Immunol. 2007;120(4):863–9.CrossRefPubMedGoogle Scholar
  36. 36.
    Polosa R, Al-Delaimy WK, Russo C, Piccillo G, Sarvà M. Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir Res. 2005;6(1):153.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Niggemann B, Jacobsen L, Dreborg S, Ferdousi HA, Halken S, Høst A, et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy. 2006;61(7):855–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Meadows A, Kaambwa B, Novielli N, Huissoon A, Fry-Smith A, Meads C, et al. A systematic review and economic evaluation of subcutaneous and sublingual allergen immunotherapy in adults and children with seasonal allergic rhinitis. Health Technol Assess. 2013;17(27):vi. xi–xiv, 1-322CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Möller C, Dreborg S, Ferdousi HA, Halken S, Høst A, Jacobsen L, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002;109(2):251–6.CrossRefPubMedGoogle Scholar
  41. 41.
    Halken S, Larenas-Linnemann D, Roberts G, Calderón MA, Angier E, Pfaar O, et al. EAACI guidelines on allergen immunotherapy: prevention of allergy. Pediatr Allergy Immunol. 2017;28:728–45.CrossRefPubMedGoogle Scholar
  42. 42.
    Platts-Mills TAE, de Weck AL. Dust mite allergens and asthma—a worldwide problem. J Allergy Clin Immunol. 1989;83(2 Pt 1):416–27.CrossRefGoogle Scholar
  43. 43.
    Sporik R, Holgate ST, Platts-Mills TAE, Cogswell JJ. Exposure to house-dust mite allergen (Der p I) and the development of asthma in childhood. N Engl J Med. 1990;323(8):502–7.CrossRefPubMedGoogle Scholar
  44. 44.
    Meng Q, Liu X, Li P, He L, Xie J, Gao X, et al. The influence of house dust mite sublingual immunotherapy on the TSLP-OX40L signaling pathway in patients with allergic rhinitis. Int Forum Allergy Rhinol. 2016;6(8):862–70.CrossRefPubMedGoogle Scholar
  45. 45.
    Ulrik CS, Backer V. Markers of impaired growth of pulmonary function in children and adolescents. Am J Respir Crit Care Med. 1999;160(1):40–4.CrossRefPubMedGoogle Scholar
  46. 46.
    Huang F-L, Liao E-C, Yu, S-J. House dust mite allergy: its innate immune response and immunotherapy. Immunobiology. 2018;223(3):300–302.  https://doi.org/10.1016/j.imbio.2017.10.035.CrossRefPubMedGoogle Scholar
  47. 47.
    Venn A, Lewis S, Cooper M, Hill J, Britton J. Questionnaire study of effect of sex and age on the prevalence of wheeze and asthma in adolescence. BMJ. 1998;316(7149):1945–6.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Geier DA, Kern JK, Geier MR. Demographic and neonatal risk factors for childhood asthma in the USA. J Matern Fetal Neonatal Med. 2017:1–5.Google Scholar
  49. 49.
    O’Connor GT, Lynch SV., Bloomberg GR, Kattan M, Wood RA, Gergen PJ, et al. Early-life home environment and risk of asthma among inner-city children. Allergy Clin Immunol. 2017.  https://doi.org/10.1016/j.jaci.2017.06.040.
  50. 50.
    Ferrini M, Carvalho S, Cho YH, Postma B, Miranda Marques L, Pinkerton K, et al. Prenatal tobacco smoke exposure predisposes offspring mice to exacerbated allergic airway inflammation associated with altered innate effector function. Part Fibre Toxicol. 2017;14(1):30.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Makadia LD, Roper PJ, Andrews JO, Tingen MS. Tobacco use and smoke exposure in children: new trends, harm, and strategies to improve health outcomes. Curr Allergy Asthma Rep. 2017;17(8):55.CrossRefPubMedGoogle Scholar
  52. 52.
    Tanaka K, Miyake Y, Furukawa S, Arakawa M. Secondhand smoke exposure and risk of wheeze in early childhood: a prospective pregnancy birth cohort study. Tob Induc Dis. 2017;15(1):30.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Polosa R, Knoke JD, Russo C, Piccillo G, Caponnetto P, Sarvà M, et al. Cigarette smoking is associated with a greater risk of incident asthma in allergic rhinitis. J Allergy Clin Immunol. 2008;121(6):1428–34.CrossRefPubMedGoogle Scholar
  54. 54.
    Diaz-Sanchez D, Rumold R, Gong H. Challenge with environmental tobacco smoke exacerbates allergic airway disease in human beings. J Allergy Clin Immunol. 2006;118(2):441–6.CrossRefPubMedGoogle Scholar
  55. 55.
    Polosa R, Russo C, Caponnetto P, Bertino G, Sarvà M, Antic T, et al. Greater severity of new onset asthma in allergic subjects who smoke: a 10-year longitudinal study. Respir Res. 2011;12(1):16.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Platts-Mills TAE. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med. 2001;164(supplement_1):S1–5.CrossRefPubMedGoogle Scholar
  57. 57.
    Platts-Mills TAE, Woodfolk JA. Allergens and their role in the allergic immune response. Immunol Rev. 2011;242(1):51–68.CrossRefPubMedGoogle Scholar
  58. 58.
    Makinen T, Lehtimäki L, Kinnunen H, Nieminen R, Kankaanranta HME. Bronchial diffusing capacity of nitric oxide is increased in patients with allergic rhinitis. Int Arch Allergy Immunol. 2009;148(2):154–60.CrossRefPubMedGoogle Scholar
  59. 59.
    Ciprandi G, Tosca MA, Capasso M. Exhaled nitric oxide in children with allergic rhinitis and/or asthma: a relationship with bronchial hyperreactivity. J Asthma. 2010;47(10):1142–7.CrossRefPubMedGoogle Scholar
  60. 60.
    Panganiban RP, Wang Y, Howrylak J, Chinchilli VM, Craig TJ, August A, et al. Circulating microRNAs as biomarkers in patients with allergic rhinitis and assthma. J Allergy Clin Immunol. 2016;137(5):1423–32.CrossRefPubMedGoogle Scholar
  61. 61.
    Hu D, Zhang Z, Ke X, Kang H, Hong S. A functional variant of miRNA-149 confers risk for allergic rhinitis and comorbid asthma in Chinese children. Int J Immunogenet. 2017;44(2):62–70.CrossRefPubMedGoogle Scholar
  62. 62.
    Luo X, Hong H, Tang J, Wu X, Lin Z, Ma R, et al. Increased expression of miR-146a in children with allergic rhinitis after allergen-specific immunotherapy. Allergy Asthma Immunol Res. 2016;8(2):132–40.CrossRefPubMedGoogle Scholar
  63. 63.
    Lu L-F, Boldin MP, Chaudhry A, Lin L-L, Taganov KD, Hanada T, et al. Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell. 2010;142(6):914–29.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Wallace D, Dykewicz M, Bernstein D, Blessingmoore J, Cox L, Khan D, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol. 2008;122(2):S1–84.CrossRefPubMedGoogle Scholar
  65. 65.
    Brożek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol. 2010;126(3):466–76.CrossRefPubMedGoogle Scholar
  66. 66.
    Larché M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006;6(10):761–71.CrossRefPubMedGoogle Scholar
  67. 67.
    Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008;8(3):218–30.CrossRefPubMedGoogle Scholar
  68. 68.
    Burks AW, Calderon MA, Casale T, Cox L, Demoly P, Jutel M, et al. Update on allergy immunotherapy: American academy of allergy, asthma & immunology/European academy of allergy and clinical immunology/PRACTALL consensus report. J Allergy Clin Immunol. 2013;131(5):1288–1296.e3.CrossRefPubMedGoogle Scholar
  69. 69.
    Şahin E, Bafaqeeh SA, Güven SG, Çetinkaya EA, Muluk NB, Coşkun ZO, et al. Mechanism of action of allergen immunotherapy. Am J Rhinol Allergy. 2016;30(5):1–3.CrossRefGoogle Scholar
  70. 70.
    Polosa R. Can immunotherapy prevent progression to asthma in allergic individuals? J Allergy Clin Immunol. 2002;110(4):672–3.CrossRefPubMedGoogle Scholar
  71. 71.
    Baena-Cagnani CE, Larenas-Linnemann D, Teijeiro A, Canonica GW, Passalacqua G. Will sublingual immunotherapy offer benefit for asthma? Curr Allergy Asthma Rep. 2013;13(6):571–9.CrossRefPubMedGoogle Scholar
  72. 72.
    Purello-D’Ambrosio F, Gangemi S, Merendino RA, Isola S, Puccinelli P, Parmiani S, et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy. 2001;31(8):1295–302.CrossRefPubMedGoogle Scholar
  73. 73.
    Des Roches A, Paradis L, Menardo JL, Bouges S, Daurés JP, Bousquet J. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J Allergy Clin Immunol. 1997;99(4):450–3.CrossRefPubMedGoogle Scholar
  74. 74.
    Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy. 2001;31(9):1392–7.CrossRefPubMedGoogle Scholar
  75. 75.
    Marogna M, Tomassetti D, Bernasconi A, Colombo F, Massolo A, Businco ADR, et al. Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Ann Allergy Asthma Immunol. 2008;101(2):206–11.CrossRefPubMedGoogle Scholar
  76. 76.
    Inal A, Altintas DU, Yilmaz M, Karakoc GB, Kendirli SG, Sertdemir Y. Prevention of sew sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol. 2007;17(2):85–91.PubMedGoogle Scholar
  77. 77.
    Novembre E, Galli E, Landi F, Caffarelli C, Pifferi M, De Marco E, et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2004;114(4):851–7.CrossRefPubMedGoogle Scholar
  78. 78.
    Polosa R, Li Gotti F, Mangano G, Paolino G, Mastruzzo C, Vancheri C, et al. Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis. Allergy. 2004;59(11):1224–8.CrossRefPubMedGoogle Scholar
  79. 79.
    Milani M, Pecora S, Burastero S, Group on behalf of EIS. Observational study of sublingual specific immunotherapy in persistent and intermittent allergic rhinitis: the EFESO trial. Curr Med Res Opin. 2008;24(9):2719–24.CrossRefPubMedGoogle Scholar
  80. 80.
    • Karakoc-Aydiner E, Eifan A, Baris S, Gunay E, Akturk H, Akkoc T, et al. Long-term effect of sublingual and subcutaneous immunotherapy in dust mite–allergic children with asthma/rhinitis: a 3-year prospective randomized controlled trial. J Investig Allergol Clin Immunol. 2015;25(255):334–42. This Randomized Controlled Trial shows the efficacy and the prevention effect of SIT in Dust Mite allergic children with AR or mild asthma. PubMedGoogle Scholar
  81. 81.
    Valovirta E, Petersen TH, Piotrowska T, Laursen MK, Andersen JS, Sørensen HF, et al. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018;141(2):529-538.  https://doi.org/10.1016/j.jaci.2017.06.014.CrossRefPubMedGoogle Scholar
  82. 82.
    British Thoracic Society and Scottish Intercollegiate Guidelines Network. British guideline on the management of asthma. 2016. Available from: https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016/.
  83. 83.
    Nurmatov U, Dhami S, Arasi S, Roberts G, Pfaar O, Muraro A, et al. Allergen immunotherapy for allergic rhinoconjunctivitis: a systematic overview of systematic reviews. Clin Transl Allergy. 2017;7:24.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Di Bona D, Plaia A, Leto-Barone MS, La Piana S, Macchia L, Di Lorenzo G. Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review. Allergy. 2017;72(5):691–704.CrossRefPubMedGoogle Scholar
  85. 85.
    • Kristiansen M, Dhami S, Netuveli G, Halken S, Muraro A, Roberts G, et al. Allergen immunotherapy for the prevention of allergy: a systematic review and meta-analysis. Pediatr Allergy Immunol. 2017;28(1):18–29. This systematic review provides evidences of a reduced short-term risk of developing asthma in allergic rhinitis subjects treated with SIT. CrossRefPubMedGoogle Scholar
  86. 86.
    Ridolo E, Incorvaia C, Gritti BL, Passalacqua G. The current overuse and misuse of meta-analyses on sublingual immunotherapy: the case of grass pollen allergy. Curr Opin Allergy Clin Immunol. 2017;17(1):12–6.CrossRefPubMedGoogle Scholar
  87. 87.
    Abramson MJ, Puy RM, Weiner JM. Allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2003;4:CD001186.Google Scholar
  88. 88.
    Penagos M, Passalacqua G, Compalati E, Baena-Cagnani CE, Orozco S, Pedroza A, et al. Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age. Chest. 2008;133(3):599–609.CrossRefPubMedGoogle Scholar
  89. 89.
    Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefler SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med. 2006;354(19):1985–97.CrossRefPubMedGoogle Scholar
  90. 90.
    Bisgaard H, Hermansen MN, Loland L, Halkjaer LB, Buchvald F. Intermittent inhaled corticosteroids in Infants with episodic wheezing. N Engl J Med. 2006;354(19):1998–2005.CrossRefPubMedGoogle Scholar
  91. 91.
    Murray CS, Woodcock A, Langley SJ, Morris J, Custovic A, IFWIN study team. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet (Lond Engl). 2006;368(9537):754–62.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Jaymin B. Morjaria
    • 1
    • 2
  • Massimo Caruso
    • 3
  • Rosalia Emma
    • 3
  • Cristina Russo
    • 4
  • Riccardo Polosa
    • 3
    • 5
  1. 1.Department of Respiratory MedicineRoyal Brompton & Harefield Hospital NHS Foundation TrustHarefieldUK
  2. 2.Imperial CollegeHarefield HospitalHarefieldUK
  3. 3.Department of Clinical and Experimental MedicineUniversity of CataniaCataniaItaly
  4. 4.MCAU ARNAS GaribaldiCataniaItaly
  5. 5.Department of Internal and Emergency MedicineAOU “Policlinico – Vittorio Emanuele”CataniaItaly

Personalised recommendations